DLBCL Infopoint 2026

Dear colleagues!
our Insights in DLBCL: New Horizons 2026 meeting was a great success with superb scientific lectures and fruitful discussions, giving insights in different therapeutic approaches across Europe and the U.S.
Our new debate-format was received very well.

We are happy that so many of you gave valuable feedback to the event. We hope to include some of the ideas in the future.
Thank you for your excellent overall rating of 4.65/5 stars!

A big thank you goes out to all speakers and participants for making this happen.
And of course a special thank you goes out to our sponsors who have made this meeting possible.
This said, I am happy to launch the 2026 DLBCL-infopoint, enabling you to relive the event.

We are looking forward to welcoming you again at Insights in DLBCL: New Horizons 2027!
Let us keep discovering and learning!

Best regards
Johannes Düll
Senior physician
Universitätsklinik Würzburg

Welcome and introduction
Dr. med. Johannes Düll

What‘s hot and what‘s not? DLBCL-specific highlights of ASH 2025
Prof. Dr. med. Max Topp

ctDNA – a new approach in the field – The concept of rolling reporter
Dr. rer. nat. Manja Meggendorfer,
Dr. med. Johannes Düll

FDG PET vs. ctDNA MRD. Will PET survive? Or do we need imaging follow ups?
Dr. med. Maximilian Scheifele

Debate: Nuclear medicine vs. MRD approach

The future is now? Chemofree for everyone in first line and possible sequencing strategies
Professor Jason Westin

Deep dive into bridging radiotherapy – revisiting concepts, fields and doses
PD Dr. med. habil. Michael Oertel

Second line DLBCL: CAR T for everyone? CAR T vs. Bispecs and chemofree: which treatment fits for which patient?
Professor Catherine Thieblemont

Post CAR T and beyond: alternativ treatments and combinations needed – new hope in later lines?
Professor Pieternella Lugtenburg, MD, PhD

First line treatment: Bispec, small molecules and ADCs: what will change the future treatment landscape in DLBCL
Prof. Dr. med. Björn Chapuy

Case studies (second line/third line and beyond) with focus on treatment decision and sequencing of therapies
Florian Eisele, MD

AbbVie-sponsored talk:
Elevating standards: Treatment management strategies of bispecific antibodies in DLBCL
Dr. Cathy Burton, MD

With the kind support of our sponsors:

Melden Sie sich jetzt für unseren Newsletter an